Speciality Plastics

Nemera

Broader sector Private

Headquarters: La Verpillière, FR
Segment: Speciality Plastics
Stories held: 2
Last story: 22 Sep 2026

Nemera designs, develops and manufactures drug delivery devices and combination products for pharmaceutical, biotech and generics customers, including auto-injectors, syringe safety systems and inhalation and ophthalmic devices. The French group operates production sites in France, Germany, Poland, the United States and Brazil and ships more than a billion devices a year across 54 countries.

2026 2

2 stories · 2026

Products & Innovation 22 Sep 2026

Schott Pharma and Nemera launch combined self-injection syringe system

Schott Pharma and Nemera have launched a passive safety system pairing Schott's 5.5ml syriQ BioPure prefillable glass syringe with Nemera's Safe'n'Sound safety device, targeting subcutaneous self-injection of large-volume biologic drugs. The companies say the pre-aligned platform is already available for technical assessment and compatibility studies, and will be shown at CPHI Milan and PDA in early October 2026. They describe it as the first such combination built around a 5.5ml prefillable glass syringe.

Why this mattersA pre-validated syringe-and-safety-device combination lowers technical risk for biologics makers shifting therapies from intravenous to home subcutaneous delivery.

The system pairs Schott Pharma's 5.5ml syriQ BioPure prefillable glass syringe with Nemera's Safe'n'Sound passive safety device.
Launch was announced 22 September 2026.
The companies describe it as the industry's first passive safety system built around a 5.5ml prefillable glass syringe.
It targets subcutaneous self-injection of large-volume and biologic drugs, including homecare use.
The product will be exhibited at CPHI Milan on 6-8 October 2026 and PDA 2026 on 6-7 October 2026.
It is already available for technical assessment, compatibility studies and development programmes.

Schott AG Nemera counterparty

Sources nemera.net

Operations & Footprint 16 Sep 2026

Nemera opens 7,200 m2 drug-delivery device hall in Normandy

Nemera has inaugurated a new 7,200 m2 production hall, Hall 3, at its Ponts-et-Marais site in Seine-Maritime, France, to expand manufacturing capacity for drug-delivery devices. The hall includes a 2,600 m2 cleanroom and will house production of the SP9 pump, allowing the SP2 pump to be centralised at the nearby Le Treport site. Combined, the two sites could add up to 120 million devices in output.

Why this mattersUp to 120 million additional devices across the two Seine-Maritime sites adds European dosing-device capacity for drugmakers and frees Le Treport to specialise on one pump.

The 7,200 m2 Hall 3, including a 2,600 m2 cleanroom, was inaugurated on 16 September 2026 after construction began in June 2025.
The facility sits on a 46,000 m2 plot and will manufacture the SP9 pump, freeing Le Treport to centralise SP2 pump production.
Combined output across Ponts-et-Marais and Le Treport could increase by up to 120 million devices.
About 100 employees will join the site over the next two years.
The plant targets ISO 14001 and ISO 50001 certification plus a BREEAM Good rating, and runs on electricity only.
Nemera employs more than 3,300 people worldwide and reports annual revenue of EUR 700m across 7 production sites on 3 continents.

Nemera

Sources sallespropres.fr FR